Tearsheet

Tactile Systems Technology (TCMD)

Market Price (12/15/2025): $27.74 | Market Cap: $619.1 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Tactile Systems Technology (TCMD)

Market Price (12/15/2025): $27.74
Market Cap: $619.1 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.9%, FCF Yield is 13%	Trading close to highs Dist 52W High is -3.3%, Dist 3Y High is -3.3%	Stock price has recently run up significantly 6M Rtn6 month market price return is 183%
1	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -21%
2	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13%
3	Megatrend and thematic drivers Megatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include Remote Patient Monitoring, Show more.

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.9%, FCF Yield is 13%
1	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -21%
2	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13%
3	Megatrend and thematic drivers Megatrends include Digital Health & Telemedicine, Aging Population & Chronic Disease, and Precision Medicine. Themes include Remote Patient Monitoring, Show more.
4	Trading close to highs Dist 52W High is -3.3%, Dist 3Y High is -3.3%
5	Stock price has recently run up significantly 6M Rtn6 month market price return is 183%

Valuation, Metrics & Events

	12/15/25	2024	2023	2022	2021
Share Price CYE	$27.74	$17.13	$14.30	$11.48	$19.03
Market Cap CYE ($ Mil)	619.1	411.3	336.9	232.0	377.7
Total Debt ($ Mil)	16.7	45.1	50.4	72.2	80.6
Total Cash ($ Mil)	80.8	108.9	75.2	38.1	40.7
Enterprise Value ($ Mil)	555.0	456.4	387.3	304.2	458.3
Valuation Ratios
P/S TTM	1.0	1.4	1.2	0.9	1.8
P/EBIT TTM	11.7	16.0	16.5	-18.2	-213.0
P/E TTM	16.9	24.1	11.5	-12.9	-31.8
Sector Ratios
P/S TTM (Sector)	11.4	10.5	8.0	5.0	10.4
P/EBIT TTM (Sector)	29.1	31.2	26.5	17.6	29.4
P/E TTM (Sector)	37.5	39.9	36.4	22.9	42.6

	12/15/25	2024	2023
Share Price CYE	$27.74	$17.13	$14.30
Market Cap CYE ($ Mil)	619.1	411.3	336.9
Total Debt ($ Mil)	16.7	45.1	50.4
Total Cash ($ Mil)	80.8	108.9	75.2
Enterprise Value ($ Mil)	555.0	456.4	387.3
Valuation Ratios
P/S TTM	1.0	1.4	1.2
P/EBIT TTM	11.7	16.0	16.5
P/E TTM	16.9	24.1	11.5
Sector Ratios
P/S TTM (Sector)	11.4	10.5	8.0
P/EBIT TTM (Sector)	29.1	31.2	26.5
P/E TTM (Sector)	37.5	39.9	36.4

	TCMD	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	0.3
Rev Chg Q	17.3%	15.9%
Rev Chg LTM	9.3%	13.2%
Rev Chg 3Y Avg	10.0%	12.2%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	0.0
Op Mgn LTM	7.4%	37.5%
CFO/Rev LTM	13.4%	35.5%
Net Inc Mgn	5.8%	27.6%
VALUATION	LOW
P/S	1.0	11.4
P/CFO	7.4	30.6
P/FCF	7.8	54.0
P/E	17.0	37.5
STABILITY	VERY GOOD
Debt/Equity	0.05	0.03
Cash/Assets	0.31	0.16

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Number of Patients Served	over 79,000	12312024	Link
Number of Sales Representatives	329	11042025	Link
Number of patents	31	11042018	Link
Number of patients enrolled in head and neck lymphedema trial	236	10282025	Link
Number of clinical trial centers for head and neck lymphedema trial	10	10282025	Link

Upcoming
2/17/2026	Earnings Release	Rev: - EPS: -

TCMD Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

Here are the key points for the significant movement in Tactile Systems Technology (TCMD) stock during the latter half of 2025: 1. Strong Third Quarter 2025 Financial Performance and Raised Guidance.

Tactile Systems Technology reported robust Q3 2025 financial results on November 3, 2025, with total revenue increasing 17% year-over-year to $85.8 million. The company's net income rose to $8.2 million, or $0.36 per diluted share, from $5.2 million, or $0.21 per diluted share, in Q3 2024. Furthermore, Adjusted EBITDA significantly improved to $14.4 million compared to $10.7 million in the prior year. This strong performance led management to raise its full-year 2025 revenue guidance to a range of $317 million to $321 million, signaling an 8%-10% growth, up from the previous range of $310 million to $315 million. Following this announcement, the stock saw a substantial surge, including a 22.13% gain in after-hours trading and a 39.38% jump on November 4, 2025. 2. Exceeding Second Quarter 2025 Earnings Expectations.

On August 4, 2025, Tactile Systems Technology reported its second-quarter 2025 financial results, surpassing analyst expectations for both revenue and earnings per share. The company posted revenue of $78.91 million, which was a 4.6% increase over analyst consensus estimates, and an EPS of $0.14, beating the projected $0.11 by 27%. This strong financial beat, driven by a 52% increase in airway clearance product sales, led to an after-hours gain of approximately 8.7% and a 20.12% pre-market surge on August 5, 2025. 3. Initiation of a Second Share Repurchase Program.

In conjunction with its strong Q3 2025 financial results, Tactile Systems Technology announced the authorization of a second share repurchase program of up to $25.0 million of the company's common stock on November 3, 2025. This followed the completion of a $30 million share repurchase program in Q2 2025, with $16.5 million repurchased during that quarter. Share repurchase programs often signal management's confidence in the company's valuation and future prospects, which can be a positive catalyst for stock price appreciation. 4. Positive Clinical Data and Product Development.

Tactile Medical announced six-month data demonstrating sustained benefits of its Flexitouch® Plus system as a first-line therapy for treating lymphedema in head and neck cancer patients in Q3 2025. This positive clinical evidence reinforces the effectiveness and market potential of its core products. Earlier in the year, in Q1 2025, the company also expanded the launch of its Nimbl product to include patients with lower extremity lymphedema, targeting a larger market segment. 5. Favorable Analyst Sentiment and Upgrades.

Following the impressive Q3 2025 earnings, several analysts reacted positively. BTIG upgraded Tactile Systems Technology's stock to a "Buy" rating, and Piper Sandler raised its price target for TCMD from $14 to $20. This positive analyst sentiment and increased price targets can attract further investor interest and contribute to upward stock momentum. One report also noted a price target increase by 42.57% to $24.48 in November 2025.

Show less

Stock Movement Drivers

Fundamental Drivers

The 105.9% change in TCMD stock from 9/14/2025 to 12/14/2025 was primarily driven by a 65.6% change in the company's P/E Multiple.

	9142025	12142025	Change
Stock Price ($)	13.51	27.82	105.92%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	298.85	311.51	4.24%
Net Income Margin (%)	5.06%	5.83%	15.32%
P/E Multiple	20.64	34.18	65.57%
Shares Outstanding (Mil)	23.09	22.32	3.35%
Cumulative Contribution			105.69%

LTM = Last Twelve Months as of date shown

Market Drivers

9/14/2025 to 12/14/2025

	Return	Correlation
TCMD	105.9%
Market (SPY)	3.7%	-4.5%
Sector (XLV)	11.5%	14.1%

Fundamental Drivers

The 182.7% change in TCMD stock from 6/15/2025 to 12/14/2025 was primarily driven by a 137.2% change in the company's P/E Multiple.

	6152025	12142025	Change
Stock Price ($)	9.84	27.82	182.72%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	293.16	311.51	6.26%
Net Income Margin (%)	5.52%	5.83%	5.57%
P/E Multiple	14.41	34.18	137.22%
Shares Outstanding (Mil)	23.71	22.32	5.87%
Cumulative Contribution			181.75%

LTM = Last Twelve Months as of date shown

Market Drivers

6/15/2025 to 12/14/2025

	Return	Correlation
TCMD	182.7%
Market (SPY)	14.5%	0.7%
Sector (XLV)	13.7%	19.2%

Fundamental Drivers

The 55.3% change in TCMD stock from 12/14/2024 to 12/14/2025 was primarily driven by a 22.8% change in the company's P/E Multiple.

	12142024	12142025	Change
Stock Price ($)	17.91	27.82	55.29%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	285.05	311.51	9.28%
Net Income Margin (%)	5.42%	5.83%	7.63%
P/E Multiple	27.82	34.18	22.85%
Shares Outstanding (Mil)	23.99	22.32	6.95%
Cumulative Contribution			54.54%

LTM = Last Twelve Months as of date shown

Market Drivers

12/14/2024 to 12/14/2025

	Return	Correlation
TCMD	55.3%
Market (SPY)	13.9%	17.2%
Sector (XLV)	10.7%	27.5%

Fundamental Drivers

The 150.2% change in TCMD stock from 12/15/2022 to 12/14/2025 was primarily driven by a 108.8% change in the company's P/S Multiple.

	12152022	12142025	Change
Stock Price ($)	11.12	27.82	150.18%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	234.61	311.51	32.78%
P/S Multiple	0.95	1.99	108.80%
Shares Outstanding (Mil)	20.14	22.32	-10.82%
Cumulative Contribution			147.25%

LTM = Last Twelve Months as of date shown

Market Drivers

12/15/2023 to 12/14/2025

	Return	Correlation
TCMD	96.9%
Market (SPY)	48.0%	20.5%
Sector (XLV)	18.2%	27.1%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
TCMD Return	-33%	-58%	-40%	25%	20%	65%	-58%
Peers Return	25%	9%	-19%	3%	39%	-24%	19%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	111%
Monthly Win Rates [3]
TCMD Win Rate	25%	25%	42%	67%	58%	67%
Peers Win Rate	63%	53%	42%	52%	57%	42%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
TCMD Max Drawdown	-54%	-58%	-66%	-13%	-22%	-45%
Peers Max Drawdown	-33%	-16%	-40%	-23%	-17%	-37%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ELMD, ENOV, ITGR, AVNS, MASI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/12/2025 (YTD)

How Low Can It Go

Unique Key	Event	TCMD	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-89.5%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	853.9%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-55.7%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	125.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-45.7%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	84.3%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days

Compare to A, ATEC, CERS, BLLN, BNBX

In The Past

Tactile Systems Technology's stock fell -89.5% during the 2022 Inflation Shock from a high on 2/12/2021. A -89.5% loss requires a 853.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Tactile Systems Technology (TCMD)

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

AI Generated Analysis | Feedback

'ResMed for lymphedema treatment'

'Insulet (Omnipod) for chronic swelling management'

AI Generated Analysis | Feedback

Flexitouch Plus System: An advanced pneumatic compression device used for at-home treatment of lymphedema and chronic venous insufficiency.
Entre System: A basic pneumatic compression device designed for the management and treatment of lymphedema.
AffloVest: A portable high-frequency chest wall oscillation (HFCWO) therapy device used for airway clearance in patients with respiratory conditions.

AI Generated Analysis | Feedback

Tactile Systems Technology (TCMD) - Major Customers

Tactile Systems Technology (TCMD) primarily sells its medical devices, such as the Flexitouch Plus system, directly to individual patients who have received a prescription from their healthcare providers. Therefore, its major customers can be categorized by the medical conditions they treat:

Patients suffering from Lymphedema: This includes individuals with primary lymphedema (due to hereditary factors) and secondary lymphedema (often resulting from cancer treatment, surgery, or trauma) affecting various body parts.
Patients suffering from Chronic Venous Insufficiency (CVI): Specifically, those with advanced stages of CVI who experience symptoms like leg swelling, pain, and skin changes, and are prescribed pneumatic compression therapy to manage their condition.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Sheri L. Dodd, Chief Executive Officer

Ms. Sheri L. Dodd has served as the Director and Chief Executive Officer of Tactile Systems Technology since July 2024. Her career in the healthcare industry spans nearly 30 years, encompassing global pharmaceutical, medical device, and digital health sectors. Before joining Tactile Medical, she was the President of Medtronic Canada. She also led Medtronic's Care Management Services business, which focused on caring for complex patients at home, and managed Medtronic's non-intensive diabetes therapy business. Her experience also includes senior roles at Medtronic plc, where she oversaw commercial and clinical functions, and Johnson & Johnson, where she worked on health economics and reimbursement strategies. Additionally, Ms. Dodd contributed to global health initiatives during her time with the World Health Organization. She became a member of Tactile's Board of Directors in January 2021.

Elaine Birkemeyer, Chief Financial Officer

Ms. Elaine Birkemeyer has been the Chief Financial Officer of Tactile Systems Technology since March 2023. She brings over 25 years of experience in finance, accounting, and business strategy, with significant senior leadership roles in large divisions within the healthcare, consumer, and retail industries, including multiple Fortune 500 companies. Prior to her role at Tactile Medical, she served as Chief Financial Officer of Rally Health, a digital health company wholly owned by UnitedHealth Group. She also held the position of Chief Financial Officer for UnitedHealth's Care Solutions portfolio. Her experience at UnitedHealth Group also includes leading finance for its Optum Operations business as Vice President and later Senior Vice President. Earlier in her career, Ms. Birkemeyer was a Senior Finance Manager for Sleep Number Corporation and held various roles of increasing responsibility at Target Corporation.

William W. Burke, Chairman Executive Board

Mr. William W. Burke has served as the Chairman of Tactile Systems Technology since 2015. His previous roles include serving as the President of Austin Highlands Advisors LLC. He also served as a Member of the Board of Directors at Invuity Inc. Currently, he is a Member of the Board of Directors at Nalu Medical Inc and Ceribell.

David J. Kaercher, Chief Information Officer

Mr. David J. Kaercher is the Chief Information Officer of Tactile Systems Technology. His prior experience includes serving as Chief Information Officer for multiple Blue Cross and Blue Shield plans. He was also the Senior Vice President for US Bank Technology and Operations Services (TOS) and Vice President of Allianz Life Technology. Additionally, Mr. Kaercher worked as a Director for Best Buy Technology and as a Manager/Consultant for IBM.

Antonios P. Gasparis, MD, Chief Medical Officer

Dr. Antonios P. Gasparis has been the Chief Medical Officer of Tactile Systems Technology since 2023. Before joining the company, he served as the System Chief, Venous Disease of Northwell Health. He also held the position of Director of Stony Brook Vein Center at Stony Brook University Medical Center.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Tactile Systems Technology (TCMD) primarily focuses on developing and providing medical devices for the treatment of chronic conditions such as lymphedema, chronic venous insufficiency (CVI), and bronchiectasis. The company's main products include the Flexitouch Plus System for lymphedema, the Entre Plus System for venous disorders, and the AffloVest for airway clearance in bronchiectasis patients.

The combined addressable market opportunity for lymphedema and bronchiectasis is estimated at $10 billion in the U.S..
Specifically, the lymphedema treatment market in the U.S. is projected to grow from $0.95 billion in 2025 to $1.46 billion by 2030.

AI Generated Analysis | Feedback

Tactile Systems Technology (TCMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:

Continued Strong Growth in Airway Clearance Products: The company's airway clearance products, particularly the AffloVest system, have demonstrated significant year-over-year revenue growth. For example, in Q3 2025, revenue from airway clearance products increased by 71% year-over-year. Tactile Systems Technology anticipates growth for its airway clearance product line to be between 52% and 55% for the full year 2025, driven by increased durable medical equipment (DME) partnerships and market awareness.
Lymphedema Product Line Momentum and Nimbl Platform Expansion: While growth in the lymphedema segment has been more modest, the company is seeing recovery and expects continued improvement. Sales and rentals of lymphedema products, including the Flexitouch, Entrée, and Nimbl systems, increased by 11% year-over-year in Q3 2025. The expanded launch of the Nimbl platform to include patients with lower extremity conditions, which represents the largest segment of the lymphedema market, is a significant driver. Management expects lymphedema revenue growth to be 3% to 4% for the full year 2025.
Sales Force Expansion and Enhanced Productivity: Tactile Systems Technology is investing in and optimizing its sales organization. This includes increasing its sales headcount to the largest field presence in its history (329 representatives as of Q3 2025) and implementing new customer relationship management (CRM) tools and data-driven sales management strategies. These initiatives are expected to boost sales force productivity and more efficiently reach lymphedema patients, with returns from these investments materializing over multiple years.
Favorable Medicare Policy Shift: A significant driver for future growth in the lymphedema market is the favorable Medicare policy shift from Local Coverage Determinations (LCD) to a National Coverage Determination (NCD) for lymphedema pneumatic compression devices. This change is expected to expand access to advanced pump therapy for patients, driving further improvement into Q4 2025 and 2026.
Product Innovation and Portfolio Development: The company continues to focus on product innovation. This includes the submission of a 510(k) for a next-generation AffloVest system, which is expected to offer reduced weight, improved connectivity, and a better fit. Additionally, the strategic buildup of its patent portfolio around proprietary pneumatic compression technologies positions Tactile Systems Technology to capture disproportionate market share in the expanding lymphedema treatment market.

AI Generated Analysis | Feedback

Share Repurchases

On November 3, 2025, Tactile Systems Technology authorized a new share repurchase program for up to $25 million of its common stock.
The share repurchase program is effective from November 3, 2025, and is set to expire on November 3, 2027.
The company anticipates funding the repurchases through its existing cash reserves and future cash flows.

Capital Expenditures

In the last 12 months, Tactile Systems Technology reported capital expenditures of -$2.33 million.
Projected capital expenditures are $3 million for 2025, $3 million for 2026, and $4 million for 2027.
These capital expenditures are estimated to represent approximately 1% of the company's revenue annually from 2025 through 2029.

Better Bets than Tactile Systems Technology (TCMD)

	TCMD	Better Performance than TCMD
Metric	Value	INDUSTRY: Life Sciences Tools & Services
Rev Chg LTM	9.3%	NTRA (38.2%), GH (30.4%), IRTC (25.5%), EXAS (14.5%), MEDP (13.9%)
Rev Chg 3Y Avg	10.0%	NTRA (40.2%), GH (28.0%), IRTC (22.8%), MEDP (19.9%), EXAS (15.5%)
Op Mgn LTM	7.4%	MTD (28.1%), A (21.3%), DHR (19.0%), TMO (18.4%), IQV (14.2%)
CFO/Rev LTM	13.4%	DHR (26.0%), MTD (25.3%), A (22.0%), IQV (17.6%), TMO (17.5%)
FCF/Rev LTM	12.6%	MTD (22.6%), DHR (20.7%), A (16.0%), TMO (14.0%), IQV (13.9%)
Total Yield	5.9%	PAVM (33.3%), SMLR (10.9%), CDNA (9.2%), FONR (8.2%)
P/S	1.0	ARAY (0.4), VREX (0.6), INGN (0.6), OFIX (0.7), BVS (0.8)
P/Op Inc	13.4	FONR (9.1), BVS (9.2)

	TCMD	Better Performance than TCMD
Metric	Value	SECTOR: Health Care
Rev Chg LTM	9.3%	LLY (36.8%), ISRG (22.2%), BSX (21.6%), AMGN (10.6%), UNH (10.5%)
Rev Chg 3Y Avg	10.0%	LLY (23.4%), ISRG (16.3%), BSX (15.6%), UNH (11.4%), AMGN (11.2%)
Op Mgn LTM	7.4%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), ABT (17.6%)
CFO/Rev LTM	13.4%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), ABT (20.8%), LLY (20.5%)
FCF/Rev LTM	12.6%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), ABT (15.8%), TMO (14.0%)
Total Yield	5.9%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), AMGN (7.9%), ABT (7.7%)
P/S	1.0	CVS (0.2), MCK (0.2), CI (0.3), ELV (0.4), UNH (0.7)
P/Op Inc	13.4	HCA (9.2), MRK (9.4), PFE (9.4), UNH (11.9), GILD (12.4)

	TCMD	Better Performance than TCMD
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	9.3%	NVDA (65.2%), AVGO (28.0%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%)
Rev Chg 3Y Avg	10.0%	NVDA (91.6%), AVGO (24.0%), MSFT (13.2%), AMZN (11.3%), GOOGL (11.0%)
Op Mgn LTM	7.4%	NVDA (58.8%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	13.4%	MSFT (50.0%), NVDA (44.4%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	12.6%	AVGO (41.6%), NVDA (41.3%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%)
Total Yield	5.9%	XOM (9.8%), BAC (7.7%), JPM (6.7%), HD (6.6%), BRK-B (6.2%)
P/S	1.0	GM (0.3), FDX (0.6), UPS (0.8), DELL (0.9), CMCSA (0.9)
P/Op Inc	13.4	VZ (5.9), BUD (7.7), T (8.3), COP (9.4), BN (12.9)

		Best Bets In Health Care Sector
	TCMD	RPRX	HALO	DOCS	UTHR	CPRX	HRMY	LGND	ISRG	GMED	MD
What You Pay
P/E	17.0	19.9	14.4	54.3	14.4	11.1	8.5	71.4	58.1	18.2	8.7
P/EBIT	11.7	9.6	11.3	55.6	10.9	9.3	6.5	51.9	56.6	17.8	5.9
What You Get
Rev Chg Q	17.3%	7.9%	22.1%	23.2%	6.8%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%
Rev Chg LTM	9.3%	3.7%	31.2%	20.2%	13.5%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%
Rev Chg 3Y Avg	10.0%	1.5%	29.0%	17.4%	19.0%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%
FCF/Rev 3Y Avg	11.3%	115.2%	45.0%	42.7%	34.3%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Can Tactile Systems Technology Stock Hold Up When Markets Turn?	Return

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to TCMD. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	15.0%	15.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-5.1%	-5.1%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.0%	9.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.0%	16.0%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	15.0%	15.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-5.1%	-5.1%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.0%	9.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.0%	16.0%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
TLRY	Tilray Brands	12.9	44.1%	-8.6%
RZLT	Rezolute	0.2	28.6%	-63.3%
CRON	Cronos	1.3	14.7%	61.9%
YOU	Clear Secure	4.0	13.3%	58.5%
RIVN	Rivian Automotive	22.5	12.1%	38.5%
EVCM	EverCommerce	2.2	10.9%	9.7%
LULU	Lululemon Athletica	24.5	9.6%	-46.4%
NX	Quanex Building Products	0.8	9.5%	-30.9%
OXM	Oxford Industries	0.5	9.4%	-53.1%
IIPR	Innovative Industrial Properties	1.6	8.9%	-5.9%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FRMI	Fermi	7.1	-33.8%
LENZ	LENZ Therapeutics	0.5	-26.0%	-37.2%
AIP	Arteris	0.7	-17.2%	59.9%
MOD	Modine Manufacturing	7.4	-15.3%	20.7%
FBYD	Falcons Beyond Global	0.4	-15.2%	40.7%
OKLO	Oklo	12.2	-15.1%	311.8%
SEI	Solaris Energy Infrastructure	2.0	-14.8%	62.6%
SNDK	SanDisk	30.1	-14.7%
NXDR	Nextdoor	0.9	-14.4%
RCUS	Arcus Biosciences	2.3	-14.4%	44.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
WVE	WAVE Life Sciences	2.7	121.1%	33.9%
TLRY	Tilray Brands	12.9	65.3%	-8.6%
TERN	Terns Pharmaceuticals	4.1	53.3%	712.3%
PLAB	Photronics	2.1	50.4%	54.1%
FULC	Fulcrum Therapeutics	0.8	46.1%	176.6%
WRBY	Warby Parker	3.4	46.0%	13.2%
PL	Planet Labs PBC	5.5	42.8%	351.5%
ALEX	Alexander & Baldwin	1.5	37.5%	22.5%
KYMR	Kymera Therapeutics	7.8	34.6%	122.9%
CRON	Cronos	1.3	31.3%	61.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
RZLT	Rezolute	0.2	-82.7%	-63.3%
FBYD	Falcons Beyond Global	0.4	-44.0%	40.7%
FRMI	Fermi	7.1	-33.4%
LENZ	LENZ Therapeutics	0.5	-32.1%	-37.2%
GOGO	Gogo	0.7	-27.9%	-37.1%
ELVN	Enliven Therapeutics	0.9	-22.7%	-25.1%
CRK	Comstock Resources	6.3	-20.8%	18.9%
BE	Bloom Energy	22.3	-20.3%	327.6%
PHR	Phreesia	1.0	-19.9%	-35.4%
MVST	Microvast	1.0	-19.7%	45.4%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.8	310.0%	466.9%
WVE	WAVE Life Sciences	2.7	138.1%	33.9%
TERN	Terns Pharmaceuticals	4.1	121.7%	712.3%
ALMS	Alumis	0.9	119.3%	46.2%
CDTX	Cidara Therapeutics	5.9	106.0%	720.9%
SGML	Sigma Lithium	1.2	87.2%	-2.6%
ANNX	Annexon	0.7	75.0%	-3.1%
NUVB	Nuvation Bio	2.9	71.0%	216.9%
ARWR	Arrowhead Pharmaceuticals	9.7	69.2%	272.8%
SVRA	Savara	1.5	68.0%	125.4%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.2	-82.0%	-63.3%
FRMI	Fermi	7.1	-53.6%
JANX	Janux Therapeutics	0.9	-46.4%	-71.4%
UP	Wheels Up Experience	0.5	-41.9%	-57.4%
AGIO	Agios Pharmaceuticals	1.6	-37.5%	-17.0%
ARDT	Ardent Health	1.2	-37.4%	-48.5%
CTEV	Claritev	0.6	-36.1%
METC	Ramaco Resources	1.0	-35.9%	54.3%
QURE	uniQure	1.1	-35.2%	10.5%
IBTA	Ibotta	0.6	-34.6%	-67.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
TLRY	Tilray Brands	12.9	44.1%	-8.6%
RZLT	Rezolute	0.2	28.6%	-63.3%
CRON	Cronos	1.3	14.7%	61.9%
YOU	Clear Secure	4.0	13.3%	58.5%
RIVN	Rivian Automotive	22.5	12.1%	38.5%
EVCM	EverCommerce	2.2	10.9%	9.7%
LULU	Lululemon Athletica	24.5	9.6%	-46.4%
NX	Quanex Building Products	0.8	9.5%	-30.9%
OXM	Oxford Industries	0.5	9.4%	-53.1%
IIPR	Innovative Industrial Properties	1.6	8.9%	-5.9%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FRMI	Fermi	7.1	-33.8%
LENZ	LENZ Therapeutics	0.5	-26.0%	-37.2%
AIP	Arteris	0.7	-17.2%	59.9%
MOD	Modine Manufacturing	7.4	-15.3%	20.7%
FBYD	Falcons Beyond Global	0.4	-15.2%	40.7%
OKLO	Oklo	12.2	-15.1%	311.8%
SEI	Solaris Energy Infrastructure	2.0	-14.8%	62.6%
SNDK	SanDisk	30.1	-14.7%
NXDR	Nextdoor	0.9	-14.4%
RCUS	Arcus Biosciences	2.3	-14.4%	44.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
WVE	WAVE Life Sciences	2.7	121.1%	33.9%
TLRY	Tilray Brands	12.9	65.3%	-8.6%
TERN	Terns Pharmaceuticals	4.1	53.3%	712.3%
PLAB	Photronics	2.1	50.4%	54.1%
FULC	Fulcrum Therapeutics	0.8	46.1%	176.6%
WRBY	Warby Parker	3.4	46.0%	13.2%
PL	Planet Labs PBC	5.5	42.8%	351.5%
ALEX	Alexander & Baldwin	1.5	37.5%	22.5%
KYMR	Kymera Therapeutics	7.8	34.6%	122.9%
CRON	Cronos	1.3	31.3%	61.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
RZLT	Rezolute	0.2	-82.7%	-63.3%
FBYD	Falcons Beyond Global	0.4	-44.0%	40.7%
FRMI	Fermi	7.1	-33.4%
LENZ	LENZ Therapeutics	0.5	-32.1%	-37.2%
GOGO	Gogo	0.7	-27.9%	-37.1%
ELVN	Enliven Therapeutics	0.9	-22.7%	-25.1%
CRK	Comstock Resources	6.3	-20.8%	18.9%
BE	Bloom Energy	22.3	-20.3%	327.6%
PHR	Phreesia	1.0	-19.9%	-35.4%
MVST	Microvast	1.0	-19.7%	45.4%

Peer Comparisons for Tactile Systems Technology

Peers to compare with:

Financials

	TCMD	ELMD	ENOV	ITGR	AVNS	MASI	Median
Name	Tactile .	Electrom.	Enovis	Integer	Avanos M.	Masimo
Mkt Price	27.82	29.85	26.47	72.72	11.75	138.34	28.84
Mkt Cap	0.6	0.2	1.5	2.6	0.5	7.5	1.1
Rev LTM	312	66	2,233	1,831	700	2,182	1,265
Op Inc LTM	23	10	-82	241	31	133	27
FCF LTM	39	9	23	120	75	168	57
FCF 3Y Avg	33	7	-47	85	49	93	41
CFO LTM	42	9	217	204	104	208	154
CFO 3Y Avg	35	8	114	193	71	147	92

Growth & Margins

	TCMD	ELMD	ENOV	ITGR	AVNS	MASI	Median
Name	Tactile .	Electrom.	Enovis	Integer	Avanos M.	Masimo
Rev Chg LTM	9.3%	16.1%	11.6%	9.5%	2.7%	38.5%	10.6%
Rev Chg 3Y Avg	10.0%	16.1%	13.0%	11.6%	7.0%	11.4%	11.5%
Rev Chg Q	17.3%	15.1%	8.6%	8.4%	4.3%	8.2%	8.5%
QoQ Delta Rev Chg LTM	4.2%	3.5%	2.0%	2.0%	1.1%	1.3%	2.0%
Op Mgn LTM	7.4%	15.7%	-3.7%	13.1%	4.4%	6.1%	6.8%
Op Mgn 3Y Avg	6.4%	12.9%	-4.1%	12.2%	3.6%	8.9%	7.7%
QoQ Delta Op Mgn LTM	1.1%	0.6%	0.9%	0.0%	-1.8%	2.0%	0.8%
CFO/Rev LTM	13.4%	14.0%	9.7%	11.1%	14.9%	9.5%	12.3%
CFO/Rev 3Y Avg	12.1%	13.3%	5.4%	11.6%	10.3%	8.1%	10.9%
FCF/Rev LTM	12.6%	13.0%	1.0%	6.6%	10.7%	7.7%	9.2%
FCF/Rev 3Y Avg	11.3%	11.7%	-2.7%	5.0%	7.1%	5.3%	6.2%

Valuation

	TCMD	ELMD	ENOV	ITGR	AVNS	MASI	Median
Name	Tactile .	Electrom.	Enovis	Integer	Avanos M.	Masimo
Mkt Cap	0.6	0.2	1.5	2.6	0.5	7.5	1.1
P/S	1.0	3.8	0.8	2.0	0.8	3.7	1.5
P/EBIT	11.7	19.7	-1.3	22.8	-1.1	-46.7	5.3
P/E	17.0	30.3	-1.3	41.7	-1.1	-14.0	7.9
P/CFO	7.4	26.8	8.0	17.8	5.1	38.3	12.9
Total Yield	5.9%	3.3%	-78.8%	2.4%	-87.4%	-7.1%	-2.4%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	10.0%	3.9%	-1.6%	2.5%	7.0%	1.1%	3.2%
D/E	0.1	0.0	0.8	0.4	0.2	0.1	0.2
Net D/E	-0.2	-0.1	0.8	0.3	0.1	0.0	0.1

Returns

	TCMD	ELMD	ENOV	ITGR	AVNS	MASI	Median
Name	Tactile .	Electrom.	Enovis	Integer	Avanos M.	Masimo
1M Rtn	17.4%	18.1%	-11.7%	4.6%	3.2%	-8.5%	3.9%
3M Rtn	105.9%	25.0%	-16.6%	-28.2%	-3.8%	-6.2%	-5.0%
6M Rtn	182.7%	48.7%	-17.0%	-38.5%	-2.9%	-14.2%	-8.5%
12M Rtn	55.3%	5.9%	-42.6%	-47.6%	-34.6%	-21.5%	-28.0%
3Y Rtn	150.2%	197.9%	-50.9%	8.3%	-55.3%	-4.1%	2.1%
1M Excs Rtn	13.5%	18.0%	-14.9%	5.0%	0.3%	-7.3%	2.6%
3M Excs Rtn	102.6%	17.6%	-21.4%	-30.6%	-7.4%	-8.3%	-7.9%
6M Excs Rtn	168.5%	34.5%	-31.3%	-52.8%	-17.1%	-28.4%	-22.8%
12M Excs Rtn	35.6%	-10.5%	-56.3%	-61.1%	-50.3%	-33.9%	-42.1%
3Y Excs Rtn	95.5%	112.4%	-124.7%	-72.3%	-128.3%	-74.3%	-73.3%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/3/2025	2/18/2025	2/20/2024	2/21/2023	2/23/2022	2/23/2021	2/26/2020
Key Financials
Total Revenue	312	293	274	247	208	187	189
EBITDA	33	32	26	2	2	-1	14
Operating Income	23	22	18	-13	-2	-4	10
Net Income	18	17	29	-18	-12	-1	11
EPS	0.78	0.71	1.24	-0.89	-0.60	-0.03	0.58
Growth Rates
Total Revenue Growth	9.3%	6.8%	11.2%	18.6%	11.2%	-1.2%	31.8%
EBITDA Growth	0.4%	22.5%	1412.1%	-9.9%	332.4%	-105.9%	108.7%
Operating Income Growth	4.5%	22.9%	241.4%	-624.1%	51.4%	-134.6%	251.1%
Net Income Growth	17.6%	-40.5%	259.6%	-51.3%	-1805.0%	-105.7%	65.7%
Margins
EBITDA Margin	10.6%	11.0%	9.6%	0.7%	0.9%	-0.4%	7.4%
Operating Income Margin	7.4%	7.6%	6.6%	-5.2%	-0.8%	-1.9%	5.5%
Net Income Margin	5.8%	5.8%	10.4%	-7.2%	-5.7%	-0.3%	5.8%
Cash & Debt
Total Cash	81	109	75	38	41	59	53
Total Debt	17	45	50	72	81	21	17
Net Debt / (Cash)	-64	-64	-25	34	40	-37	-37
Cash Flows
Net Cash from Operations	42	41	36	5	3	3	3
Free Cash from Operations	39	38	33	3	0	1	-3
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	30	4	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/3/2025	8/4/2025	5/5/2025	2/18/2025	11/4/2024	8/5/2024	5/6/2024	2/20/2024	11/6/2023	8/7/2023	5/8/2023	2/21/2023
Key Financials Quarterly
Total Revenue	86	79	61	86	73	73	61	78	70	68	59	74
Ebitda	13	7	-2	15	9	8	-1	16	7	4	-2	10
Operating Income	11	4	-5	13	7	6	-3	12	5	2	-4	8
Net Income	8	3	-3	10	5	4	-2	8	22	-0	-2	5
EPS	0.37	0.14	-0.13	0.40	0.21	0.18	-0.09	0.35	0.95	-0.00	-0.09	0.23
Key Financials TTM
Total Revenue TTM	312	299	293	293	285	282	277	274	271	266	258	247
Ebitda TTM	33	29	31	32	33	30	25	24	18	13	7	2
Operating Income TTM	23	19	21	22	22	20	16	16	11	4	-2	-13
Net Income TTM	18	15	16	17	15	33	28	29	25	0	-4	-18
Growth Rates Quarterly
Total Revenue Growth	17.3%	7.8%	0.3%	10.2%	5.0%	7.1%	3.8%	5.1%	6.6%	14.6%	22.7%	19.7%
EBITDA Growth	39.9%	-20.7%	-216.0%	-4.0%	44.5%	124.8%	72.1%	66.1%	176.6%	257.9%	72.1%	79.1%
Operating Income Growth	61.7%	-30.2%	-53.2%	1.3%	37.9%	184.2%	22.1%	57.4%	403.5%	150.4%	74.5%	108.5%
Net Income Growth	59.2%	-25.2%	-34.6%	18.5%	-76.9%	4398.0%	-17.1%	77.5%	1078.5%	97.8%	87.9%	161.7%
Margins Quarterly
EBITDA Margin	15.5%	8.4%	-3.1%	17.7%	13.0%	11.4%	-1.0%	20.4%	9.4%	5.4%	-3.7%	12.9%
Operating Income Margin	12.8%	5.2%	-7.4%	14.6%	9.3%	8.0%	-4.9%	15.9%	7.1%	3.0%	-6.5%	10.6%
Net Income Margin	9.6%	4.1%	-4.9%	11.4%	7.1%	5.9%	-3.6%	10.6%	32.0%	-0.1%	-3.2%	6.3%
Cash & Debt
Total Cash	81	96	98	109	96	87	75	75	80	76	69	38
Total Debt	17	42	44	45	47	48	49	50	68	70	71	72
Net Debt / (Cash)	-64	-54	-55	-64	-50	-40	-26	-25	-11	-7	2	34
Cash Flows Quarterly
FCF from Operations	10	15	0	16	10	13	1	18	4	14	-1	4
Cash Flows TTM
FCF from Operations TTM	42	42	40	41	43	37	37	36	21	20	8	5
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	17	10	4	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	32.6%	11.1%	-11.3%	32.0%	14.6%	11.8%	-6.2%	23.0%	12.2%	5.0%	-3.5%	12.7%
Return on Invested Capital (ROIC) TTM
ROIC TTM	17.4%	13.1%	12.7%	13.7%	11.6%	14.4%	10.9%	10.4%	6.9%	1.0%	-0.8%	-7.7%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Lymphedema products	242	212	203
Airway clearance products	33	35	5
Entre system				23
Flexitouch System				164	171
ACTitouch/Entré Systems					18
Total	274	247	208	187	189

Price Behavior

Price Behavior

Market Price	$27.82
Market Cap ($ Bil)	0.6
First Trading Date	07/28/2016
Distance from 52W High	-3.3%
	50 Days	200 Days
DMA Price	$20.84	$14.26
DMA Trend	up	up
Distance from DMA	33.5%	95.1%
	3M	1YR
Volatility	89.7%	68.3%
Downside Capture	-152.88	59.52
Upside Capture	232.83	95.46
Correlation (SPY)	-5.1%	17.2%

TCMD Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-1.72	-0.66	-0.49	0.01	0.58	0.78
Up Beta	-1.10	-0.65	-0.08	0.71	0.58	0.80
Down Beta	-4.65	-0.31	-1.02	-0.86	0.49	0.71
Up Capture	396%	214%	193%	183%	73%	88%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	9	22	35	68	119	378
Down Capture	-415%	-295%	-219%	-148%	73%	89%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	10	19	27	55	124	362

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of TCMD With Other Asset Classes (Last 1Y)
	TCMD	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	51.5%	7.9%	13.8%	61.2%	3.6%	-3.9%	-7.4%
Annualized Volatility	67.7%	17.4%	19.7%	19.4%	15.9%	17.7%	35.6%
Sharpe Ratio	0.87	0.28	0.54	2.34	0.04	-0.38	-0.05
Correlation With Other Assets		27.6%	17.1%	-11.1%	-7.6%	24.8%	3.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of TCMD With Other Asset Classes (Last 5Y)
	TCMD	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-8.0%	8.1%	14.5%	18.1%	11.5%	4.4%	36.1%
Annualized Volatility	60.0%	14.5%	17.1%	15.5%	18.9%	18.9%	48.9%
Sharpe Ratio	0.10	0.38	0.69	0.94	0.50	0.15	0.63
Correlation With Other Assets		27.4%	30.0%	1.5%	-0.3%	28.5%	13.6%

Based On 10-Year Data

		Comparison of TCMD With Other Asset Classes (Last 10Y)
	TCMD	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	10.3%	9.7%	14.4%	14.3%	5.8%	5.3%	73.6%
Annualized Volatility	56.9%	16.7%	18.0%	14.7%	17.7%	20.8%	55.9%
Sharpe Ratio	0.41	0.48	0.69	0.80	0.26	0.22	0.93
Correlation With Other Assets		31.3%	33.5%	0.5%	6.7%	29.6%	8.7%

Short Interest

Short Interest: As Of Date	11282025
Short Interest: Shares Quantity	1,857,367
Short Interest: % Change Since 11152025	10.4%
Average Daily Volume	507,045
Days-to-Cover Short Interest	3.66
Basic Shares Quantity	22,318,570
Short % of Basic Shares	8.3%

Returns Analyses

	Title
0	Can Tactile Systems Technology Stock Hold Up When Markets Turn?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/3/2025	40.6%	57.8%	70.0%
8/4/2025	26.8%	23.1%	33.9%
5/5/2025	-29.0%	-30.3%	-27.3%
2/18/2025	-13.3%	-18.1%	-22.8%
11/4/2024	-11.1%	5.6%	25.9%
8/5/2024	13.9%	12.4%	15.2%
5/6/2024	1.8%	-2.5%	-14.7%
2/20/2024	-3.2%	5.8%	9.9%
...
SUMMARY STATS
# Positive	10	12	13
# Negative	12	10	9
Median Positive	14.0%	11.3%	15.2%
Median Negative	-12.0%	-12.6%	-14.2%
Max Positive	40.6%	57.8%	70.0%
Max Negative	-29.0%	-30.3%	-44.2%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11032025	10-Q 9/30/2025
6302025	8042025	10-Q 6/30/2025
3312025	5052025	10-Q 3/31/2025
12312024	2182025	10-K 12/31/2024
9302024	11042024	10-Q 9/30/2024
6302024	8052024	10-Q 6/30/2024
3312024	5062024	10-Q 3/31/2024
12312023	2202024	10-K 12/31/2023
9302023	11062023	10-Q 9/30/2023
6302023	8072023	10-Q 6/30/2023
3312023	5082023	10-Q 3/31/2023
12312022	2212023	10-K 12/31/2022
9302022	11072022	10-Q 9/30/2022
6302022	8012022	10-Q 6/30/2022
3312022	5022022	10-Q 3/31/2022
12312021	2232022	10-K 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Tactile Systems Technology (TCMD)

Market Price (12/15/2025): $27.74 | Market Cap: $619.1 MilSector: Health Care | Industry: Life Sciences Tools & Services

Tactile Systems Technology (TCMD)

Market Price (12/15/2025): $27.74Market Cap: $619.1 MilSector: Health CareIndustry: Life Sciences Tools & Services

Valuation, Metrics & Events

TCMD Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Tactile Systems Technology (TCMD)

Tactile Systems Technology (TCMD) - Major Customers

Interactive Breakdown

Better Bets than Tactile Systems Technology (TCMD)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Tactile Systems Technology

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/15/2025): $27.74 | Market Cap: $619.1 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/15/2025): $27.74
Market Cap: $619.1 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services